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Poster Session I S227earlier years were more prevalent in non-responders. With adjust-
ments for age and gender recommendations where appropriate, me-
dian adherence to recommended guidelines was 75%. (Table) An
ordinal regression analysis showed that lower adherence was signif-
icantly associated with autologous HCT, concerns about medical
costs, non-White race, male gender, and self-reported lack of knowl-
edge about recommended screening tests, all p\0.01.While 98% of
respondents had medical insurance, 24% reported one or more ac-
tions to limit medical costs: decreasing the dose of prescribed med-
ication, not filling a prescription, not making medical appointments,
not using health services such as physical therapy, or not having a rec-
ommended medical test performed. 3% reported filing for bank-
ruptcy due to medical expenses. Multivariate modeling showed
that concern about costs was associated with female gender, age
younger than 65 years, and low physical and mental functional status
as measured by the SF-12, all p\ 0.01.
Conclusion: Although self-reported adherence to screening prac-
tices overall was high among respondents, selected practices
had\50% adherence, and lower adherence overall was associated
with type of HCT, race, gender, and self-reported financial concerns
and lack of knowledge. 24% of respondents reported that costs influ-
enced their use of medical care. Future work attempting to increase
adherence to recommended preventive care should specifically target
selected practices associated with lower adherence and must recog-
nize that financial concerns may be a significant barrier for some pa-
tients.
Table. Use of preventive care
Asymptomatic
Preventive
care
Target Population
and Frequency N eligible AdherenceBlood
pressure
testAll, every clinic visit,
at least every 2
years1849 95% within
2 yearsDental
examAll, annually 1849 91% within
2 yearsCholesterol test Women older
than 45 and
men older
than 35,
every 5 years153689% within
5 years
Breast examination Women 20-40
every 3
years;
women over
40, annually86992% within
2 yearsMammogram Women over
40, annually 72489% within
2 yearsGynecologic
examWomen greater
than 21,
annually or at
least every 3
years86987% within
2 years
Pap smear Women greater
than 21, annually
or at least every
3 years869 85% within
2 yearsColonoscopy or
sigmoidoscopyAll greater than
50 years,
every 5 years
forsigmoidoscopy
or 10 years for
colonoscopy1222 77% within
5 years(Continued )Table. (Continued )Preventive
careAsymptomatic
Target Population
and Frequency N eligible AdherenceStool occult
blood
testAll greater than 50
years, annually1222 44% within
2 yearsSkin exam
by
medical
providerAll, annually 1849 62% within
2 yearsSkin exam
by
patient
or familyAll, annually 1849 65% within
2 yearsThyroid
blood
testAll, annually 1849 47% within
2 years186
NEUROCOGNITIVE OUTCOMES OF INFANTS WITH ACUTE LYMPHOBLAS-
TIC LEUKEMIA (ALL) UNDERGOING A TOTAL BODY IRRADIATION (TBI)
CONTAINING MYELOABLATIVE HEMATOPOIETIC STEM CELL TRANS-
PLANT (HSCT) BEFORE 18 MONTHS OF AGE
Danner-Koptik, K.1, Golden, S.2, Kletzel, M.1,3, Hijiya, N.1,3,
Dilley, K.1,3 1Children’s Memorial Hospital, Chicago, IL; 2Rosalind
Franklin University, Chicago, IL; 3Northwestern University, Chicago, IL
The objective of this study is to analyze the long term neurocog-
nitive (NC) effects in infants diagnosed with ALL at age less than 12
months and treated with allogeneic HSCT and TBI. Retrospective
review of medical records of eligible patients transplanted from
1992 through 2004 at a single institution was performed. Twenty pa-
tients were identified and we now report on 13 who havemore than 5
year follow-up. Among these 13 patients, 69%were male, 46%Cau-
casian, 38%Hispanic, 15% African American. 38% had central ner-
vous system involvement at diagnosis. 23% had +MLL gene
rearrangement and 8% had t (4:11). The conditioning regimen in-
cluded TBI 1200 cGy (fractions of 150  8), cyclophosphamide
60 mg/Kg daily 3 days and etoposide 1000 mg/m2 single dose (cy-
tarabine was substituted for etoposide in 1 patient). Stem cell sources
are as follows: 54%matched related donor, 8% related matched um-
bilical cord blood (UCB),and 38% unrelatedUCB.Graft versus host
disease (GvHD) prophylaxis were cyclosporine (CsA) alone (n5 3,
23%), CsA+methotrexate (MTX) (n5 7, 54%) or CsA+anti-thymo-
cyte gobulin +MTX. (n5 3, 23%). Leukemia free survival was 85%
at 5 years. Lansky functional scores were100% (n5 7), 90% (n5 2),
70% (n5 1), data in 1 patient not available. NC data was available in
10 patients. Two received formal NC evaluation via Child Psychia-
try, 7 have school individualized educational plans (IEP). Four with
an IEP are inmainstreamed classes while 3 require self-contained/as-
sisted classrooms. Two have no current IEP. 90%have age appropri-
ate social skills; 90% are in organized sports/extra-curricular
activities. 20% are currently in high school, the remainder in ele-
mentary school and advancing. TBI is generally avoided in this pa-
tient population to minimize late effects, and while all patients in
this cohort have some measurable degree of NC effect, their overall
level of function allows for healthy school, family, social, and sport
participation.187
PATIENT CHARACTERISTICS, QUALITY OF LIFE, MOOD STATES, AND
COPING OF OVER 60 COMPARED TO UNDER 60 YEAR OLD AUTOLOGOUS
STEM CELL PATIENTS PRE- AND POST- TRANSPLANT
McLellan, L.1, Dabney, J.1, Rybicki, L.1, Foster, L.W.2, Visnosky, M.1,
Curtis, J.1, Bolwell, B.1 1Cleveland Clinic, OH; 2Cleveland State Univer-
sity, OH
This analysis looks at the differences in experience of transplant of
patients 60+ and under 60 years of age undergoing autologous stem
cell transplantation (ASCT). We reviewed 304 adult patients who
underwent ASCT between June 2003 and December 2007, and
S228 Poster Session Iwho completed three psychometric instruments prior to priming for
stem cell collection and at approximately day 42 post ASCT. The
three instruments are the Functional Assessment of Cancer Therapy
– BoneMarrowTransplant (FACT-BMT), measuring quality of life;
Brief COPE, measuring coping with illness; and Profile of Mood
States (POMS) short form, measuring mood states.
In comparisons of patient and transplant characteristics including
(but not limited to) gender, race, diagnosis, length of stay, and read-
missions, the following significant differences were found between
patients 60+ and under 60 years of age: Patients 60+ had a slightly
longer length of stay (median 21 vs. 20 days, p5 0.013), were
more likely to have NHL (75% vs. 61%), and less likely to have
Hodgkins (2% vs.19%, p\0.001).
Many significant differences were found in quality of life scores
between patients 60+ and under 60. Patients 60+ reported better so-
cial, emotional, and functional well-being at both pre-transplant and
at day 42 post-transplant (p# 0.05). The 60+ group also reported
better physical well-being at pre-transplant compared to the under
60 group (p5 0.022). Regarding significant differences in coping,
the 60+ group used less coping techniques of self-distraction, behav-
ioral disengagement, venting, planning, humor, and self-blame, but
reportedmore acceptance in coping with illness (p# 0.05). There are
four significant differences between the two groups on mood states
but only at pre-transplant. The 60+ group reports less depression,
anger, tension, and confusion than the under 60 group (p# 0.05).
It is surprising patients over 60 report better quality of life, better
mood states, and less utilization of coping techniques. It seems
that older patients are more accepting of illness and impact on func-
tioning, perceive themselves as not needing as much support to cope,
and report less negative impact on mood states than their younger
counterparts.188
LONG-TERM FOLLOW-UP AFTER ALLOGENEIC HEMATOPOIETIC PRO-
GENITOR CELL TRANSPLANTATION IN PEDIATRIC PATIENTS-MULTICEN-
TER STUDY
Gorczynska, E.1, Dyla, A.1, Owoc-Lempch, J.1, Musial, J.1,
Turkiewicz, D.1, Kalwak, K.1, Ussowicz, M.1, Chybicka, A.1,
Pieczonka, A.2, Jacek, W.2, Wojcik, B.3, Kowalczyk, J.3 1Wroclaw Med-
ical University, Wroclaw, Poland; 2University of Medical Sciences,
Poznan, Poland; 3Medical University, Lublin, Poland
Hematopoietic progenitor cell transplantation (HPCT) remains
a salvage therapy for both malignant and non-malignant disorders.
However, it may result in late sequelae which negatively influence
the quality of life. The aim of this study was to evaluate the long-
term impact of HPCT on the patients’ health status. Two hundred
thirty one patients, who survived over one year after allogeneic
HPCT were included into the study. The median age at HPCT
was 11.5 years (from 4months to 18 years), the median follow-up pe-
riod was 3.5 years (from 13 months to 12 years). One hundred eighty
three subjects were transplanted due to malignant diseases (group I)
and forty eight due to non-malignant disorders (group II). The fre-
quency of late side effects, including chronic Graft-versus-Host Dis-
ease (GvHD), endocrinal dysfunctions and organs impairment, were
compared between two groups using chi2 test.
Only 65 (28.1%) patients in the study group did not suffer from
any health problems. During the follow-up 15 (8.2%) patients in
group I died due to late complications (6 cGvHD, 5 infections, 2 sec-
ond neoplasm, 1 pulmonary artery thrombosis, 1 haemorrhage). In
group II two (4.2%) patients died (1 cGvHD, 1 haemorrhage),
p5 0.34. The incidence of late sequelae in group I and II was docu-
mented respectively: cGvHD86 (47%) vs 10 (20.8%), p5 0.001; oc-
ular complications 39 (21.3%) vs 4 (8.3%), p5 0.04; skin problems
69 (37.7%) vs 6 (12.5%), p5 0.0009; hormonal dysfunction 64
(35%) vs 19 (39.6%), p5 0.55; pulmonary complications 55 (30%)
vs 9 (18.7%), p5 0.12; bone and joint impairment 32 (17.5%) vs 4
(8.3%), p5 0.12; cardiological dysfunction 25 (13.7%) vs 5
(10.4%), p5 0.55; kidney problems 5 (2.7%) vs 3 (6.2%), p5 0.23;
neurological disorders 10 (5.5%) vs 1 (2.1%), p5 0.16; second neo-
plasm 3 (1.6%) vs 1 (2.1%), p5 0.83.
Conclusions: Majority of survivors after allogeneic HPCT de-
velop late sequelae. Patients transplanted with the diagnosis of ma-
lignant disease are at higher risk of cGvHD resulting in furthercomplications, mainly skin and ocular problems. Higher incidence
of cGvHD in this cohort of patients may be due to less intensive im-
munosupressive therapy in comparison to the subjects transplanted
due to non-malignant diseases. The impact of chemotherapy used
in the treatment of malignancies prior toHPCT should also be taken
into consideration. The multidisciplinary monitoring for a pro-
longed period of time after HPCT is strongly recommended.189
MUSCLE WEAKNESS FOLLOWING ALLOGENEIC STEM CELL TRANSPLAN-
TATION: ANALYSIS OF RISK FACTORS
Kiguchi, D.2, Nawa, Y.1, Nakase, K.1, Miyazaki, Y.1, Kohashi, S.1,
Kadohisa, S.1, Tauchi, H.2, Kogami, S.2, Hara, M.1 1Ehime Prefectural
Central Hospital, Matsuyama, Japan; 2Ehime Prefectural Central Hospi-
tal, Matsuyama, Japan
Allogeneic stem cell transplantation (allo-SCT) can cause severe
adversed effects, which is associated with functional impairment
and muscle weakness. In this study, we analyzed factors affecting
muscle weakness after allo-SCT in 21 patients (13 male, 8 female)
who had allo-SCT at Ehime Prefectural Central Hospital from April
2007–March 2009, Patient ages ranged from 26–64 (median 46
years) at the time of allo-SCT. Sixteen patients received stem cells
from unrelated donors, and 5 received them from related donors.
A myeloablative conditioning regimen was chosen for 14 patients,
and 7 patients had a reduced intensity conditioning regimen. The pa-
tients received lower extremity muscle training while muscle
strength was measured at the same time by a therapeutic exercise sys-
tem (Strength Ergo 240, Mitsubishi Electric Corp., Tokyo, Japan).
Percent changes of lower extremity muscle strength before allo-
SCT and 100 days after allo-SCT for each patient was calculated,
and muscle strength was also compared using the Mann-Whitney
U test between groups divided by various factors. The average per-
cent change of lower extremity muscle strength was
-22.16 24.3%, and age group (26-46 vs. 47-64 years), sex, and con-
ditioning regimens (myeloablative or non-myeloablative) did not
significantly affect muscle strength. Patients who had higher does
of steroids showed a tendency towards greater decreases in muscle
strength (high dose, -31.06 21.0% vs. low dose, -12.36 24.8%,
P5 0.057). Source of stem cells (unrelated, -28.86 24.0% vs. re-
lated, -0.56 6.1%, P5 0.026), grades of acute GVHD (grades 0-2,
-15.46 19.1% vs. grades 3-4 -62.26 1.1%, P\0.01), and levels of
serum albumin ($3.4 g/dl, -12.56 16.5% vs. \3.4 g/dl,
-34.86 28.0%, P5 0.047) significantly affected the decrease ofmus-
cle strength.Our study suggests that muscle strengthmay be affected
by the source of stem cells, nutritious status and complications after
allo-SCT, and, patients at risk should receive more intensive therapy
to prevent loss of muscle strength after transplantation.190
A LONGITUDINAL COMPARISON OF QUALITY OF LIFE (QOL) IN PATIENTS
WITH MYELOID MALIGNANCIES UNDERGOING ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (ALLOHCT) USING MYELOABLATIVE
(MY) OR REDUCED INTENSITY CONDITIONING (RIC)
Gupta, V.1, Li, L.2, Panzarella, T.2, Khan, J.1, Galal, A.1, Kuruvilla, J.1,
Lipton, J.1, Messner, H.1, Alibhai, S.3 1Princess Margaret Hospital, Tor-
onto, ON, Canada; 2Princess Margaret Hospital, Toronto, ON, Canada;
3Toronto General Hospital, ON, Canada
There are limited data on the impact of intensity of conditioning
onQOL in patients undergoing alloHCT.We undertook a prospec-
tive study to evaluate the outcomes and QOL in patients with mye-
loid malignancies undergoing alloHCT using MY or RIC. 115
patients were enrolled from Jan 2005 to Sep 2008 and no significant
differences in the outcomes were observed in the two study cohorts at
1-year (abstract submitted separately).
Of 115 patients, 105 (91%) patients (MY, 44; RIC, 61) consented
to participate in QOL study with QOL assessments at baseline,
day30, day100, day180 and day365. QOLwas assessed by the follow-
ing measures: European Organization for Research and Treatment
of Cancer core 30-item questionnaire (QLQ-C30), Functional As-
sessment of Cancer Therapy-bone marrow transplantation subscale
(FACT-BMT), FACT anaemia and fatigue subscale (FACT-An),
